Skip to main content
. 2018 Aug 21;58(1):94–102. doi: 10.1093/rheumatology/key262

Fig. 1.

Fig. 1

Treatment survival curve for 76 systemic JIA patients: 54 tocilizumab and 22 anakinra

Survival was better on tocilizumab (89%; solid line) compared with anakinra (59%; dashed line) at one year (P = 0.002).